Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Anderson

Showing results (211-220 of 271) with videos related to

Pageof 28
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2014
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with menSharon M Seifert, David V Glidden, Amie L Meditz, et al.
BMJ Open|May 11, 2026
Positive psychological intervention to reduce HIV acquisition risk with men who use stimulants: protocol for a randomised controlled trialOmar R Valentin, Chelsea Henderson, Lara S Coffin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2021
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United StatesJill Blumenthal, Sonia Jain, Feng He, et al.
The Journal of Infectious Diseases|April 18, 2014
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trialTeri Liegler, Mohamed Abdel-Mohsen, L Gordon Bentley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2017
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, CaliforniaRaphael J Landovitz, Matthew Beymer, Ryan Kofron, et al.
AIDS (London, England)|November 26, 2015
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ringMarla J Keller, Pedro M Mesquita, Mark A Marzinke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2020
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure ProphylaxisMatthew A Spinelli, Brentton Lowery, Jennifer A Shuford, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2018
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarateChristine E MacBrayne, Kristen M Marks, Daniel S Fierer, et al.
The Pediatric Infectious Disease Journal|April 15, 2025
Pharmacokinetics of Tenofovir Diphosphate, Lamivudine Triphosphate and Emtricitabine Triphosphate in Adolescents With HIV Infection With and Without Tuberculosis CoinfectionSampson Antwi, Anthony Enimil, Hongmei Yang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2017
Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPTMariya V Sivay, Maoji Li, Estelle Piwowar-Manning, et al.
Pageof 28

Showing results (211-220 of 271) with videos related to

Sort By:
Pageof 28
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 20, 2014
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with menSharon M Seifert, David V Glidden, Amie L Meditz, et al.
BMJ Open|May 11, 2026
Positive psychological intervention to reduce HIV acquisition risk with men who use stimulants: protocol for a randomised controlled trialOmar R Valentin, Chelsea Henderson, Lara S Coffin, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 17, 2021
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United StatesJill Blumenthal, Sonia Jain, Feng He, et al.
The Journal of Infectious Diseases|April 18, 2014
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trialTeri Liegler, Mohamed Abdel-Mohsen, L Gordon Bentley, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2017
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, CaliforniaRaphael J Landovitz, Matthew Beymer, Ryan Kofron, et al.
AIDS (London, England)|November 26, 2015
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ringMarla J Keller, Pedro M Mesquita, Mark A Marzinke, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 21, 2020
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure ProphylaxisMatthew A Spinelli, Brentton Lowery, Jennifer A Shuford, et al.
The Journal of Antimicrobial Chemotherapy|May 11, 2018
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarateChristine E MacBrayne, Kristen M Marks, Daniel S Fierer, et al.
The Pediatric Infectious Disease Journal|April 15, 2025
Pharmacokinetics of Tenofovir Diphosphate, Lamivudine Triphosphate and Emtricitabine Triphosphate in Adolescents With HIV Infection With and Without Tuberculosis CoinfectionSampson Antwi, Anthony Enimil, Hongmei Yang, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 23, 2017
Characterization of HIV Seroconverters in a TDF/FTC PrEP Study: HPTN 067/ADAPTMariya V Sivay, Maoji Li, Estelle Piwowar-Manning, et al.
Pageof 28